四剂口服脊髓灰质炎疫苗与人类新生儿轮状病毒疫苗(RV3-BB)联合接种时的免疫原性
在印度尼西亚开展的一项随机安慰剂对照试验(1649人)中,两个子研究评估了RV3-BB与三价口服脊髓灰质炎疫苗(OPV组 n=282)或灭活脊髓灰质炎疫苗(IPV组 n=333)联合接种的免疫原性。结果显示,四剂OPV与RV3-BB联合接种后,对脊髓灰质炎病毒1、2、3型的血清保护率与安慰剂组相似(范围0.96-1.00);RV3-BB的血清IgA应答在OPV与IPV联合接种时总体相似。结论认为联合接种未降低任一疫苗的免疫原性。
要点
- 四剂OPV与RV3-BB联合接种后,脊髓灰质炎病毒1、2、3型血清保护率与安慰剂组相似(范围0.96-1.00)。
- RV3-BB血清IgA应答在OPV与IPV联合接种时相似,新生儿程序差值0.01(95%CI -0.12至0.14;p=0.847)。
- 婴儿程序sIgA应答差值-0.10(95%CI -0.21至-0.001;p=0.046),sIgA GMT比值1.20(95%CI 0.74-1.96;p=0.448)。
核心结论
- 在出生剂次策略下,OPV与RV3-BB轮状病毒疫苗联合接种未降低任一疫苗的免疫原性。
- 这些发现支持在常规免疫规划使用OPV或IPV的情况下使用新生儿RV3-BB疫苗。
研究设计与样本
- 随机、安慰剂对照试验,于2013年1月至2016年7月在印度尼西亚中爪哇和日惹开展,共1649名参与者。
- 参与者接受三剂口服RV3-BB,首剂于0-5天(新生儿程序)或约8周(婴儿程序)给予,或接受安慰剂。
- 两个子研究评估RV3-BB与三价OPV(OPV组,n=282)或IPV(IPV组,n=333)联合接种时的免疫原性。
- 在第1剂和第4剂OPV后采用中和试验检测针对脊髓灰质炎病毒1、2、3型的血清抗体。
主要发现
- 四剂OPV与RV3-BB联合接种后,对脊髓灰质炎病毒1、2或3型的血清保护率与安慰剂组相似(范围0.96-1.00)。
- RV3-BB血清IgA应答在OPV与IPV联合接种时相似:新生儿程序差值0.01(95%CI -0.12至0.14;p=0.847);婴儿程序差值-0.10(95%CI -0.21至-0.001;p=0.046)。
- sIgA GMT比值:新生儿程序1.23(95%CI 0.71-2.14;p=0.463);婴儿程序1.20(95%CI 0.74-1.96;p=0.448)。
临床怎么用
- 作者认为,这些发现支持在常规免疫规划使用OPV或IPV的情况下使用新生儿RV3-BB疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The RV3-BB human neonatal rotavirus vaccine was developed to provide protection from severe rotavirus disease from birth. The aim of this study was to investigate the potential for mutual interference in the immunogenicity of oral polio vaccine (OPV) and RV3-BB. METHODS: A randomized, placebo-controlled trial involving 1649 participants was conducted from January 2013 to July 2016 in Central Java and Yogyakarta, Indonesia. Participants received three doses of oral RV3-BB, with the first dose given at 0-5 days (neonatal schedule) or ~8 weeks (infant schedule), or placebo. Two sub-studies assessed the immunogenicity of RV3-BB when co-administered with either trivalent OPV (OPV group, n = 282) or inactivated polio vaccine (IPV group, n = 333). Serum samples were tested for antibodies to poliovirus strains 1, 2 and 3 by neutralization assays following doses 1 and 4 of OPV. RESULTS: Sero-protective rates to poliovirus type 1, 2 or 3 were similar (range 0.96-1.00) after four doses of OPV co-administered with RV3-BB compared with placebo. Serum IgA responses to RV3-BB were similar when co-administered with either OPV or IPV (difference in proportions OPV vs IPV: sIgA responses; neonatal schedule 0.01, 95% CI -0.12 to 0.14; p = 0.847; infant schedule -0.10, 95% CI -0.21 to -0.001; p = 0.046: sIgA GMT ratio: neonatal schedule 1.23, 95% CI 0.71-2.14, p = 0.463 or infant schedule 1.20, 95% CI 0.74-1.96, p = 0.448). CONCLUSIONS: The co-administration of OPV with RV3-BB rotavirus vaccine in a birth dose strategy did not reduce the immunogenicity of either vaccine. These findings support the use of a neonatal RV3-BB vaccine where either OPV or IPV is used in the routine vaccination schedule.
引用
- Cowley D, Sari RM, Handley A, et al. Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB). Vaccine. 2019. PMID: 31607604. doi:10.1016/j.vaccine.2019.09.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。